Morgan Leonard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Morgan Leonard has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Esther Ademola
Luxembourg Institute of Health (LIH), Transversal Translational Medicine, Strassen, Luxembourg
1 shared publication - Joëlle V. Fritz
Transversal Translational Medicine, Luxembourg Institute of Health, Luxembourg
1 shared publication - Rejko Krüger
Luxembourg Institute of Health
1 shared publication - Sibylle Béchet
Luxembourg Institute of Health (LIH), Transversal Translational Medicine, Strassen, Luxembourg
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (2) , 265-277
Precision prevention for neurodegenerative diseases: lessons learnt from Alzheimer’s disease translated into perspectives for Parkinson’s disease
Population ageing is posing significant challenges for healthcare systems and societies worldwide. Neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, are among the leading contributors to disability, dependence, and healthcare costs in ageing societies. Prevention offers the most sustainable approach to reducing the burden of neurodegenerative diseases. While Alzheimer’s disease prevention is already advancing through biomarker-based early detection, identification of modifiable risk factors, and multi-domain interventions, efforts are now turning towards Parkinson’s disease, the fastest growing neurodegenerative disorder. Using deeply phenotyped cohorts of patients with Parkinson’s disease and people with prodromal stages of neurodegenerative diseases, novel biomarkers have enabled biological classification for improved diagnosis of Parkinson’s disease, including early cognitive impairments. The expanding knowledge of Parkinson’s disease risk factors is now being translated into primary and secondary prevention concepts within integrated care settings to effectively address the burden of neurodegenerative diseases for the people affected. Integrating biomarker-based risk stratification with scalable life-style based programmes offers a realistic pathway toward precision prevention in Parkinson’s disease.
- 26 December 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (2) , 265-277
Open AccessPrecision prevention for neurodegenerative diseases: lessons learnt from Alzheimer’s disease translated into perspectives for Parkinson’s disease
Population ageing is posing significant challenges for healthcare systems and societies worldwide. Neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, are among the leading contributors to disability, dependence, and healthcare costs in ageing societies. Prevention offers the most sustainable approach to reducing the burden of neurodegenerative diseases. While Alzheimer’s disease prevention is already advancing through biomarker-based early detection, identification of modifiable risk factors, and multi-domain interventions, efforts are now turning towards Parkinson’s disease, the fastest growing neurodegenerative disorder. Using deeply phenotyped cohorts of patients with Parkinson’s disease and people with prodromal stages of neurodegenerative diseases, novel biomarkers have enabled biological classification for improved diagnosis of Parkinson’s disease, including early cognitive impairments. The expanding knowledge of Parkinson’s disease risk factors is now being translated into primary and secondary prevention concepts within integrated care settings to effectively address the burden of neurodegenerative diseases for the people affected. Integrating biomarker-based risk stratification with scalable life-style based programmes offers a realistic pathway toward precision prevention in Parkinson’s disease.